Advanced Enzyme Financial Statements

Advanced Enzyme (ADVENZYMES) reported revenue of ₹6.37B in FY2025 with net income of ₹1.31B. Total assets stood at ₹16.21B and free cash flow was ₹1.09B.

Advanced Enzyme Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		5.02B	5.36B	5.66B	6.61B	6.37B
Cost of Rev. Cost of Revenue		-990.42M	-1.10B	-1.32B	-1.45B	-1.52B
Gross Profit		4.03B	4.26B	4.34B	5.16B	4.85B
SGA Sales, General & Admin		-1.71B	-2.18B	-2.52B	-2.75B	-1.42B
Op. Income Operating Income		2.03B	1.73B	1.47B	2.06B	1.58B
PBT Profit Before Tax		2.10B	1.71B	1.40B	1.88B	1.87B
Net Income		1.46B	1.24B	1.04B	1.37B	1.31B
Dil. Shares Diluted Shares		111.81M	111.87M	111.82M	111.88M	111.99M
Diluted EPS		13.08	10.68	9.45	11.92	11.71

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Advanced Enzyme's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Advanced Enzyme Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		5.16B	6.04B	7.22B	8.10B	8.80B
Non-curr. assets Total non-current assets		6.37B	6.63B	7.00B	7.26B	7.41B
Total assets		11.53B	12.68B	14.22B	15.35B	16.21B
Curr. liabilities Total current liabilities		675.58M	604.22M	775.66M	1.06B	967.55M
Non-curr. liab. Total non-current liabilities		543.47M	668.01M	601.10M	580.26M	559.22M
Total liabilities		1.22B	1.27B	1.38B	1.64B	1.53B
Total equity		10.31B	11.40B	12.84B	13.71B	14.69B
Total liab. & eq. Total liabilities & equity		11.53B	12.68B	14.22B	15.35B	16.21B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Advanced Enzyme's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Advanced Enzyme Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		2.10B	1.71B	1.40B	1.88B	1.87B
Operating CF Cash flow Operating Activities		1.63B	1.22B	1.40B	1.41B	1.42B
Capex Investments in PPE		-195.80M	-281.16M	-381.05M	-423.13M	-338.08M
Investing CF Cash flow Investing Activities		-260.33M	-37.87M	-2.98B	-646.49M	-891.01M
Dividend Paid		-79.81M	-118.60M	-125.42M	-567.12M	-590.30M
Financing CF Cash flow Financing Activities		-263.10M	-485.00M	-257.98M	-592.38M	-725.44M
Cash (start) Cash at beginning of period		826.64M	1.92B	2.67B	964.20M	1.14B
Cash (end) Cash at end of period		1.92B	2.67B	964.20M	1.14B	942.25M
FCF Free Cash Flow		1.43B	941.75M	1.02B	990.56M	1.09B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Advanced Enzyme's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025